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Abstract
Transcranial Direct Current Stimulation (tDCS) is a method of non-invasive brain stimulation that has been frequently used
in experimental and clinical pain studies. However, the molecular mechanisms underlying tDCS-mediated pain control, and
most important its placebo component, are not completely established. In this pilot study, we investigated in vivo the
involvement of the endogenous m-opioid system in the global tDCS-analgesia experience. Nine healthy volunteers went
through positron emission tomography (PET) scans with [11C]carfentanil, a selective m-opioid receptor (MOR) radiotracer, to
measure the central MOR activity during tDCS in vivo (non-displaceable binding potential, BPND) - one of the main analgesic
mechanisms in the brain. Placebo and real anodal primary motor cortex (M1/2mA) tDCS were delivered sequentially for
20 minutes each during the PET scan. The initial placebo tDCS phase induced a decrease in MOR BPND in the periaqueductal
gray matter (PAG), precuneus, and thalamus, indicating activation of endogenous m-opioid neurotransmission, even before
the active tDCS. The subsequent real tDCS also induced MOR activation in the PAG and precuneus, which were positively
correlated to the changes observed with placebo tDCS. Nonetheless, real tDCS had an additional MOR activation in the left
prefrontal cortex. Although significant changes in the MOR BPND occurred with both placebo and real tDCS, significant
analgesic effects, measured by improvements in the heat and cold pain thresholds, were only observed after real tDCS, not
the placebo tDCS. This study gives preliminary evidence that the analgesic effects reported with M1-tDCS, can be in part
related to the recruitment of the same endogenous MOR mechanisms induced by placebo, and that such effects can be
purposely optimized by real tDCS.
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Introduction
Although the neuromechanisms of placebo analgesia are well
linked to opioid release in both forebrain structures and
descending antinociceptive systems [1–4], direct recruitment and
optimization of this endogenous resource have been a challenge
[5,6]. Recently, multiple modulatory techniques have been
investigated to non-invasively target pain related regions in the
brain, and nowadays one of the most frequently used in research is
transcranial Direct Current Stimulation (tDCS). Its surge in
clinical and scientific reports worldwide is in part due to its low
cost and simple operation. tDCS is a method of cortical excitability
modulation based on the application of a weak electrical current
that flows between electrodes directly applied to the scalp. It has
been presented as a relatively effective procedure for neurophys-
iological experiments, with few adverse events when the safety
guidelines are followed [7]. In the most conventional setup for pain
research, the anode (positive pole) is placed over the area of the
primary motor cortex (M1) and the cathode (negative pole) over
the supra-orbital (SO) region [8,9]. Regarding the analgesic
effects, significant results have been reported in various persistent
pain syndromes, such as fibromyalgia [10], central pain in
traumatic spinal cord injury [11], and chronic migraine [12].
However, neither the analgesic outcomes with tDCS are consistent
across studies [13–15], nor its endogenous neuromechanisms well
understood.
Functional magnetic resonance imaging (fMRI) and positron
emission tomography (PET) with blood flow tracers have provided
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some important information regarding pain modulatory effects of
tDCS on cortical and subcortical activity [16–18]. Lately, PET has
extended our knowledge of molecular mechanisms in the brain in
vivo when appropriate radiotracers are utilized. Maarrawi and
colleagues, using the ‘‘non-selective’’ opioid receptor radiotracer
[11C]diprenorphine, showed that surgical motor cortex stimulation
(MCS) provided analgesic relief in eight neuropathic pain patients
with concurrently reduction in opioid receptor availability in the
periaqueductal gray matter (PAG), prefrontal cortex (PFC),
anterior mid-cingulate cortex (aMCC), and cerebellum. These
data were interpreted as reflecting MCS-induced release of
endogenous opioid peptides (Maarrawi, 2007). Consistent with
those findings, the analgesic effects produced by non-invasive
motor cortex stimulation with repetitive transcranial magnetic
stimulation (rTMS) were antagonized by the opioid receptor
antagonist naloxone [19]. Interestingly, placebo analgesic effects
are also blocked by naloxone [20,21].
We have recently reported significant acute reductions in m-
opioid receptor (MOR) availability in pain-related regions during
a single session of real tDCS in a postherpetic neuralgia patient
[22]. The m-opioid system is the most important mechanism
involved in the regulation of nociceptive signals, and specific target
of several opioid analgesics currently available for clinical use. The
case report utilized [11C]carfentanil, a selective MOR radiotracer,
and the application of real tDCS was associated with significant
changes in thermal pain thresholds. Those preliminary findings
suggested that clinical outcomes observed with tDCS could be
positively associated with activation of the MOR system, which
has been similarly reported in placebo studies [1,3,5,6]. Never-
theless, there remain unknowns regarding the endogenous placebo
mechanisms contribution to the final tDCS-induced analgesia.
In this pilot study, we investigated the immediate effects of
placebo and its optimization by subsequent real tDCS on MOR
mediated neurotransmission and thermal pain thresholds in a
group of healthy subjects, applying the M1-SO tDCS montage.
We hypothesize that placebo tDCS produces immediate activation
of the MOR system, which could be optimized by real tDCS in
order to build up an effective analgesic outcome.
Materials and Methods
2.1 Subjects
Nine right-handed healthy volunteers (five males and four
females), mean age 44616, were studied. The exclusion criteria
included: A) systemic medical illnesses; B) presence of chronic pain
disorders; C) recent surgery or trauma (,6 months); D) use of
narcotic analgesics (,6 months); E) major psychiatric illnesses
(e.g., schizophrenia, major depression, suicidal ideation, or
substance abuse); and F) any PET or MRI contraindications. All
volunteers were initially screened to obtain the medical history and
to investigate possible contra-indications to MRI, PET or tDCS.
After the initial evaluation, they underwent one MRI, and two
PET scans. All neuroimaging exams were acquired in different
days. The MRI exams were acquired prior to the PET exams. The
subjects recruited were not under pharmacological treatment for
any condition and no medication was administered prior to the
experiments. This research study was conducted in accordance
with the bioethical rules for studies involving human beings of the
WMA (World Medical Association)––Declaration of Helsinki
(1990). All procedures adopted were approved by the University
of Michigan Investigational Review Board for Human Subject Use
(IRB # 24607) and the Radioactive Drug Research Committee of
the US Food and Drug Administration. All subjects gave written
informed consent prior to the participation in this study.
2.2 Neuroimaging
We used a radiotracer with specific affinity for m-opioid
receptors, [11C]carfentanil. Each participant underwent one
baseline and one tDCS PET scan using a Siemens (Knoxville,
TN) HR+ scanner in 3D mode (reconstructed images have a full-
width at half maximum (FWHM) resolution of ,5.5 mm-in-plane
and 5.0 mm axially). Both scans have a total duration of
90 minutes. Synthesis of high specific activity [11C]carfentanil
was produced by the reaction of [11C]methyliodide and a non-
methyl precursor [23,24]. Each [11C]carfentanil dose (1561 mCi,
#0.05 mg/kg) was administered in a bolus (50% of dose)/
continuous infusion protocol to more rapidly achieve steady-state
levels. PET images were reconstructed using interactive algorithms
into a 1286128 pixel-matrix in a 28.8 cm diameter field of view
(FOV). Twenty-eight image frames were obtained and co-
registered to one another. They were corrected for motion and
decay [25]. Dynamic image data for each scan were converted on
a voxel-by-voxel basis into two sets of parametric images using a
modified Logan graphical analysis using the occipital cortex as the
reference region [26]. First, a tracer transport measure (K1 ratio)
was used for MRI co-registration and normalization procedures
that were applied to the receptor measure. The receptor-related
measure, non-displaceable binding potential BPND, or receptor
availability in vivo, is proportional to Bmax/Kd (Bmax = receptor
concentration, Kd = receptor-ligand dissociation constant).
A T1-weighted anatomical MRI scan was acquired on a 3 Tesla
scanner (General Electric, Milwaukee, WI). The MRI acquisition
utilized the following sequence parameters: axial spoiled-gradient
recalled (SPGR) 3D acquisition, 15.63 bandwidth, repetition time
[TR] = 9.2 ms, echo time [TE] = 1.9 ms, inversion recovery
preparation 500 ms, flip angle = 15u, 25/26 FOV, number of
excitations [NEX] = 1, 144 contiguous slices, 1.0 mm slice
thickness, 2566256 matrix.
Images were anatomically standardized into template space
using Statistical Parametric Mapping (SPM8) software by A) co-
registering the MR scan and K1 scans; B) normalizing the MR
scan to the Montreal Neurological Institute (MNI) coordinate
system using VBM8 toolbox in SPM8 (http://dbm.neuro.uni-
jena.de/vbm8/) and C) applying the resulting deformation matrix
to the PET images. Co-registration and normalization accuracy
was verified by comparing the transformed MR and PET images
to the MNI atlas template.
2.3 Transcranial Direct Current Stimulation (tDCS)
The first PET consisted of a baseline scan, when [11C]carfenta-
nil was intravenously administered, according the protocol
described before, but no other intervention occurred. However,
to introduce the subjects to the tDCS protocol during this initial
PET, the apparatus was placed on patients’ head; and to avoid any
suspicious thoughts of deceptive interventions, we showed the end
of the electrodes disconnected from the device. During the second
PET scan, both placebo and real tDCS were performed. For this
purpose, we used a battery-driven constant current stimulator
(Soterix Medical 161 tDCS) with a pair of conductive-rubber
electrodes. Placebo tDCS was applied during the early phase of
the PET study (15 to 35 min post-tracer administration), while real
tDCS was performed during the late PET phase (60 to 80 min).
The experimental design used in this study is illustrated in
Figure 1. During placebo stimulation, 2 mA of tDCS was applied
for the initial and final 30 seconds of a 20 minutes session, as
sensations arising from tDCS are usually observed at the beginning
and end of application [27]. The anode was positioned over the
superficial area corresponding to the right M1 or C4 position,
using the 10/20 system of electrode placement and the cathode
Building up Analgesia via the Endogenous m-Opioid System by tDCS
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was placed over the contralateral supraorbital (SO) region. It is
worth mentioning that due to the size of the electrodes, the area
contacting the hand representation in the somatosensory cortex
(postcentral gyrus) was also likely covered. The same method was
used for real tDCS; however, the current was applied for the entire
20 minutes session. Each electrode was enclosed in a 35 cm2
sponge soaked with approximately 12 mL of saline solution (6 mL
per side) before the PET. We used saline solutions with lower
concentrations of NaCl (15 mM) for irrigation. Due to the long
time needed for the PET session, we developed a novel method to
optimize contact quality of electrodes during the whole period of
stimulation to avoid abrupt increases in the overall resistance that
could lead to abnormal sensations or burning during both placebo
and real tDCS. The system consisted of two syringes, each one
connected to the anodal and cathodal sponges by two long
cannulas with cross-perforations at their near ends to evenly
distribute saline solution through the sponge extension. When
contact quality decreased during PET/tDCS session, as demon-
strated in the SMARTScan tool of the device (Soterix, NY), our
investigators remotely added saline solution to the sponges until
reading of contact quality returned to optimal levels. We used
567 cm electrodes following the recommendations of previous
studies [8,28]. To assess the safety of the procedure each volunteer
was also requested to complete a questionnaire of adverse events at
the end of the second PET scan. Following this procedure, subjects
were asked if they could distinguish placebo from real tDCS. All
volunteers were blind to the treatment conditions.
2.4 Quantitative Sensory Testing (QST)
QST was performed on both sides of the face, in order to detect
variations in the cold and heat pain thresholds related to both
placebo and real tDCS. Considering that this is the first study
evaluating the effects of placebo and real tDCS on the m-opioid
system, it is also important to determine if the clinical effects of
tDCS are homunculus-specific or occur in both sides of the face.
We used Pathway Pain and Sensory Evaluation System (Medoc,
Israel) to apply thermal stimuli and record subject’s response. For
this purpose, we used a 16616 mm thermode, which contains an
extended cable length. This procedure was carried out in three
distinct time points during the second PET scan: 1- before the
exam started, 2- between placebo and real tDCS (35 to 60 min
from radiotracer administration) and 3- after real tDCS. Heat and
cold stimuli were applied to the third division of the trigeminal
nerve (V3), bilaterally. Pain thresholds were assessed with the
‘‘method of limits’’. In this method, the intensity of a stimulus is
gradually increased until the subject perceives a predefined
sensation (e.g. pain) and manually stops the stimulation [29–32].
Following a warning signal, the temperature increased from an
adaptation temperature of 30uC with a ramp rate of 1uC/s. The
volunteer was instructed to press a button as fast as possible at the
moment the stimulus became painful. Three assessments were
obtained for each stimulus, with an interstimulus interval of
40 seconds and heat and cold pain thresholds were calculated by
taking the average temperature of the three assessments. All
participants were instructed to report any unexpected sensation
arising from QST during the experiment.
2.5 Data analysis
MOR activation was measured as the reduction in MOR BPND
from baseline to the given experimental condition (placebo or real
tDCS). The effects of placebo and real tDCS were examined
separately using paired t tests. Due to the explorative nature of this
study, threshold for significance was set at p#0.001, .40 voxels,
for a priori hypothesis regions (areas shown to be involved in MOR-
mediated pain control in previous studies). The significant clusters
were extracted and the average cluster values were used to test the
potential associations between the MOR BPND data and selected
variables. Pearson’s coefficient correlation was applied to deter-
mine the degree of association between placebo and real tDCS
MOR activation in each significant cluster found.
Due to the small sample size, wide and non-Gaussian
distribution of the data, non-parametric statistical tests were
chosen to evaluate the tDCS effects on the heat and cold pain
thresholds. Although it is an explorative, pilot study, a more
conservative statistical methodology was applied, using the Fried-
man ANOVA and Nemenyi multiple comparisons test, which
permits to adequately control the type I error at the level of 5%.
Friedman ANOVA was applied to evaluate the presence of
significant variations in the cold and heat pain thresholds related
to placebo and real tDCS. When the null hypothesis could be
rejected at p,0.05, the Nemenyi test for multiple comparisons was
used to verify whether significant differences existed between any
pair of observations (baseline6sham tDCS6real tDCS). We set the
significance level at 5% and used the software SAS 6.11 (SAS
Institute, Inc., Cary, NC) to conduct this part of the statistical
analysis.
Results
All participants successfully completed the study. No major
adverse events related to PET, tDCS or QST were reported. None
of the subjects could accurately differentiate placebo and real
tDCS at the end of the PET session.
Figure 1. Experimental design used in the second PET scan. Placebo tDCS was applied during the early PET phase (15 to 35 min post-tracer
administration) and real tDCS during the late PET phase (60 to 80 min). QST was performed before the PET, in the period between placebo and real
tDCS and immediately after the PET.
doi:10.1371/journal.pone.0102350.g001
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3.1 Placebo and Real tDCS Effects on Central m-Opioid
Activation
A significant placebo tDCS-induced MOR activation was
observed in the right precuneus [(6, 234, 46), 1040 mm3,
Z = 3.5], PAG [(24, 230, 26, 712) mm3, Z = 3.9] and left
thalamus [(210, 218, 12), 280 mm3, Z = 4.2] (Figure 2 A–C). No
significant clusters were detected in the opposite contrast (i.e.,
MOR deactivation during placebo tDCS). During subsequent real
tDCS phase, clusters showing MOR activation were also found in
the left precuneus [(24, 246, 52), 952 mm3, Z = 3.1], PAG [(22,
226, 24), 472 mm3, Z = 3.4], and left PFC [(226, 12, 48),
744 mm3, Z = 3.5] (Figure 2 D–F).
Placebo and real MOR activations showed positive correlation
in the PAG and precuneus (Figure 3 A, B, D and E), but not in the
thalamus or PFC (Figure 3 C and F). Significant correlations were
observed in the following coordinates: PAG [(24, 230, 26)
rp = 0.760, p = 0.013] and left precuneus [(24, 246, 52),
rp = 0.788, p = 0.008] clusters (Figure 3 B and D, respectively),
3.2 Analgesic tDCS Effects on Heat and Cold Pain
Thresholds
Overall, the effects of real tDCS were more pronounced than
placebo tDCS effects, for both heat and cold pain thresholds
(Figures 4 and 5, respectively).
According to Friedman ANOVA, statistically significant
changes occurred in the left face heat (p = 0.032) and cold
(p = 0.012) pain thresholds throughout the experiment. Nemenyi
test for multiple comparisons identified that the left face heat pain
Figure 2. Changes in the m-opioid receptor availability induced by placebo (A–C) and real (D–E) tDCS. A and D, Representation of
precuneus MOR activation in the sagittal plane. B and E, PAG MOR activation in the axial plane. C, Left thalamus (Thal) MOR activation in the coronal
plane. F, Left prefrontal cortex (PFC) MOR activation in the axial plane. All images are radiological in orientation, threshold T 3–8.
doi:10.1371/journal.pone.0102350.g002
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threshold was significant higher after real tDCS, when compared
to baseline (Figure 4). The same test showed that the left face cold
pain threshold was significantly higher; implying increased cold
pain tolerance, after real tDCS, when compared to placebo tDCS
and baseline.
Discussion
We tested the hypothesis that placebo tDCS induces immediate
effects on endogenous m-opioid receptor (MOR)-mediated neuro-
transmission, and that such analgesic effects can be optimized at
molecular and clinical levels when real tDCS is delivered. Our
results indicate that placebo and real tDCS induced similar and
positively correlated MORs activations in the PAG and precuneus,
as well as dissimilar activations in the thalamus and PFC
respectively (Figures 2 and 3); which led to build up of effective
thermal pain analgesia when real tDCS was subsequently added to
the placebo experience.
The contribution of the m-opioid system in brain stimulation
analgesia has been suggested with MCS [33], TMS [19,34] and
more recently with tDCS [22]. However, the association of the m-
opioid transmission induced by real tDCS neuromodulation with
the placebo experience and the analgesic outcomes have not been
explored. The involvement of PAG and precuneus in central pain
processes has been shown in functional neuroimaging studies in
acute and chronic pain, including migraine [35–42]. PAG is a
region with high levels of m-opioid receptors and one the most
important areas for opioid-mediated anti-nociception
[2,35,36,43]. This particular midbrain region is considered central
in placebo mechanisms, given its involvement in descending pain
analgesia during placebo administration [1,4]. Precuneus activa-
tion during placebo anticipation has been reported in the absence
of pain, and deactivation during placebo administration [44],
potentially reflecting the participation of this region in the
integration of cognitive and sensory assessments related to pain
signal. Of note, strong precuneus activation was reported after
intravenous administration of the MOR agonist remifentanil
during fMRI, indicating that this region may also be important in
opioidergic pain modulation [45]. Furthermore, the increased
connectivity between precuneus and PAG recently demonstrated
after active electroacupunture, suggests the participation of both
regions in different modalities of pain modulation [46]. More
recently, PET studies have confirmed those findings by demon-
strating the activation of MOR neurotransmission during placebo
administration in the PAG and thalamus, among other brain
regions [1,4]. Here, the PAG, precuneus, and thalamus activations
observed for the period of our early PET/tDCS protocol are in
agreement with the notion that placebo brain stimulation prompts
Figure 3. Correlation between placebo and real tDCS-induced MOR activation. MOR BPND during placebo (x axis) and real (y axis) tDCS for
each subject in the clusters of m-opioid activation induced by placebo (A–C) and real (D–F) tDCS. The same clusters are illustrated in the figure 2.
Positive correlations can be observed in precuneus and PAG (red lines) but not in thalamus and PFC (blue lines). Statistically significant values at p,
0.05 were found in the PAG cluster activated during placebo tDCS (rp = 0.760, p = 0.013, 3B) and in the precuneus cluster activated during active tDCS
(rp = 0.788, p = 0.008, 3D).
doi:10.1371/journal.pone.0102350.g003
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Figure 4. Box plot representing tDCS (placebo and real) effects in the heat pain thresholds of both sides of the face. Statistically
significant changes occurred in the heat pain thresholds of the left face (p = 0.032).
doi:10.1371/journal.pone.0102350.g004
Figure 5. Box plot illustrating cold pain thresholds variations related to placebo and real tDCS. Statistically significant changes occurred
in the cold pain thresholds of the left face (p = 0.012) throughout the experiment.
doi:10.1371/journal.pone.0102350.g005
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endogenous MOR neurotransmission in areas implicated in pain
regulation.
Remarkably, when we subsequently added the real tDCS, there
were similar MOR activations in the precuneus and PAG
(Figure 2D and 2E), which were positively correlated with the
prior placebo tDCS (Figure 3D and 3E). One interpretation is that
the more placebo induced m-opioid neurotransmission in the PAG
and precuneus, the stronger their regional activation during real
tDCS. This observation suggests that successful M1-tDCS
analgesia depends in part on individual susceptibility to mobilize
m-opioid activity during placebo. An alternative interpretation,
given we are assessing correlation and not causality, is that the two
responses are increased but unrelated phenomena.
Conversely, this finding does not signify that MOR neurotrans-
mission elicited by real tDCS is solely based on the patient’s belief
of the therapeutic effect. In fact, the supplementary MOR
activations noted in the thalamus and PFC, respectively following
placebo and real tDCS, did not show any statistical correlation or
tendency (Figure 3 C and F).
The MOR activation in the PFC is associated with higher order
cognitive functions such as attention, decision-making and
working memory [47,48]. Different subregions of the PFC have
been implicated in pain perception and/or modulation with a
critical role in the emotional processing of pain [49–56]. Increased
cerebral perfusion has been recently demonstrated during anodal
tDCS applied to the dorsolateral PFC [57]. Moreover, it has been
shown that PFC stimulation produces its analgesic effects via
endogenous opioid release, as it is reversed by naloxone [34,58].
Finally, MCS induces opioid activation in the PFC and PAG also
correlates with pain improvement [33]. Interestingly, using a high-
resolution tDCS computational model, our group has previously
demonstrated peaks of current flow in the bilateral PFC,
suggesting that M1-tDCS can potentially directly target the
neuronal activity of this area [12]. Hence, we speculate that
indirect and direct PFC modulation by M1-tDCS might contrib-
ute to the significant regional endogenous m-opioid release, which
in turn, would contribute to the higher analgesic effects of real
tDCS.
Overall, we found significant improvement of cold and heat
pain tolerance following real tDCS, consistent with other studies
[59–65]. The large variability in the QST values found in our
study, especially for cold pain thresholds, are similar to other
reported values [66,67]. Interestingly, significant changes in the
thermal pain thresholds were only observed in the face contralat-
eral to the side where tDCS was delivered. These findings could be
explained by a direct effect of conventional M1-tDCS in cortical
and even subcortical brain structures ipsilateral to the stimulation.
Nonetheless, due to the large dimensions of the electrodes other
areas covering the cortical homunculus could also have been
stimulated [12]. High-definition tDCS may provide in the future
additional information about the sole contribution of motor and
somatosensory stimulation to placebo and real MOR mechanisms
[68]. In the current research protocol, tDCS was delivered on the
non-dominant motor cortex. It is possible that stimulation of the
dominant cortex could have produced different neuroimaging and
clinical outcomes. In addition, the effects placebo and active tDCS
in other dermatomes, outside the trigeminal territory remains to
be explored.
It is important to emphasize that our protocol aimed to
investigate the endogenous effect of placebo tDCS and its
immediate contribution and optimization by subsequent real
M1-SO tDCS, not the opposite. Although randomization and
other montages and currents would also provide important
information regarding other neuromechanisms of tDCS [27,69],
these aims were outside the scope of our study. Furthermore, it is
possible to hypothesize that increasing the sample size might
expand our results to a broader set of brain structures.
Nevertheless, the important finding of this preliminary report is
that both placebo and active tDCS induce MOR activation and,
consequently, they jointly contribute to the benefits of the
treatment in clinical samples.
Conclusions
In this preliminary report, we demonstrate, in a cohort of
healthy subjects, that placebo tDCS produces acute changes in the
endogenous MOR-mediated neurotransmission, indicating acti-
vation of the analgesic m-opioid mechanism, and that such effect is
optimized at molecular and clinical levels by real tDCS. This
suggests that M1-SO tDCS might in part recruit and effectively
potentiate the same analgesic resources elicited during placebo
experience. Further studies, assessing different study protocols (e.g.
naloxone modulation), in larger sample sizes and including chronic
pain patients, will be necessary to confirm our findings, and to
scrutinize the long-term effects of tDCS on analgesic m-opioid
activation and other brain mechanisms, before its potential
therapeutic application in chronic pain relief.
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